Emergent BioSolutions Inc. (EBS)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Total revenues | 140,900 | 222,200 | 293,800 | |
| Selling, general and administrative | 43,700 | 52,400 | 76,600 | |
| Research and development | 12,500 | 15,100 | 13,800 | |
| Impairment of long-lived assets | - | - | - | |
| Cost of product and services sales, net | 66,900 | 88,500 | 122,600 | |
| Amortization of intangible assets | 16,200 | 16,300 | 16,300 | |
| Total operating expenses | 139,300 | 172,300 | 229,300 | |
| Income (loss) from operations | 1,600 | 49,900 | 64,500 | |
| Gain (loss) on sale of business | - | - | 64,300 | |
| Other, net | -3,700 | 69,700 | 21,900 | |
| Interest expense | 14,700 | 14,700 | 8,300 | |
| Loss on assets held for sale | - | -12,200 | - | |
| Total other income (expense), net | -18,400 | 42,800 | 77,900 | |
| Income (loss) before income taxes | -16,800 | 92,700 | 142,400 | |
| Income tax provision (benefit) | -4,800 | 24,700 | 27,600 | |
| Net income (loss) | -12,000 | 68,000 | 114,800 | |
| Basic (in dollars per share) | -0.22 | 1.25 | 2.16 | |
| Basic (in shares) | 54,200,000 | 54,400,000 | 53,100,000 | |
| Diluted (in dollars per share) | -0.22 | 1.19 | 2.06 | |
| Diluted (in shares) | 54,200,000 | 57,300,000 | 55,600,000 | |